Perrigo Lights Smoking Cessation For Growth With Turnaround Woes 'Fixable'

As "market leader" in OTC nicotine replacement treatments, Perrigo should "be the one that's doing a lot of innovation," says CEO Murray Kessler. He discussed Perrigo's problems and potential sales drivers as it reported 2018 net sales of $4.7bn, down 4% , and Q4 net sales of $1.2bn, down 7%. Global consumer health product sales for year were flat at $3.9bn and Q4 sales were down 4% at $973m.

Perrigo Co. PLC acknowledges eight challenges to its turnaround but categorizes each of them as "fixable." It also identified an OTC drug category to heat up sales growth – smoking cessation products.

More from International

More from Geography